olmutinib 🐶 Veterinary Use | Indications/Contra | FAERs-F | FAERs-M | Orange Bk | BioActivity |

Stem definitionDrug idCAS RN
tyrosine kinase inhibitors 5210 1353550-13-6

Description:

MoleculeDescription

Molfile Inchi Smiles

Synonyms:

  • olmutinib
  • olita
  • BI 1482694
  • HM 61713
  • olmutinib hydrochloride
  • olmutinib HCl
Olmutinib is an oral, third-generation epidermal growth factor receptor tyrosine kinase inhibitor (EGFR TKI) for the treatment of non-small cell lung cancer (NSCLC). Third-generation EGFR TKIs with covalent binding to the receptors demonstrate irreversible enzymatic inhibition of activating EGFR mutations and T790M mutation (a common reason for acquired EGFR TKI resistance), while sparing wild-type EGFR.
  • Molecular weight: 486.59
  • Formula: C26H26N6O2S
  • CLOGP: 5.05
  • LIPINSKI: 1
  • HAC: 8
  • HDO: 2
  • TPSA: 82.62
  • ALOGS: -4.79
  • ROTB: 7

Drug dosage:

None

ADMET properties:

None

Approvals:

FDA Adverse Event Reporting System (Female)

None

FDA Adverse Event Reporting System (Male)

None

FDA Adverse Event Reporting System (Geriatric)

None

FDA Adverse Event Reporting System (Pediatric)

None

Pharmacologic Action:

Drug Use | Suggest Off label Use Form| |View source of the data|




🐶 Veterinary Drug Use

None

🐶 Veterinary products

None

Acid dissociation constants calculated using MoKa v3.0.0

Orange Book patent data (new drug applications)

None

Orange Book exclusivity data (new drug applications)

None

Bioactivity Summary:

External reference:

Pharmaceutical products:

None

olmutinib